Pfizer economic study says Sutent cost effective in mRCC
Results from an international study presented at the European Society for Medical Oncology, in Stockholm, Sweden, predict that Pfizer's Sutent (sunitinib) is cost effective as a first-line therapy for patients with metastatic renal cell carcinoma.
The world pharmaceutical giant's economic model, which was analyzed in the context of three health care systems - Sweden, Spain and the USA - predicts better outcomes with sunitinib, in terms of life years, progression-free life years and quality-adjusted life years, compared with Roche's Avastin (bevacizumab) plus interferon-alpha, Bayer's Nexavar (sorafenib) and Wyeth's Torisel (temsirolimus). In addition, sunitinib was found to be cost saving when compared with bevacizumab and IFN-alpha and temsirolimus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze